Simplify Logo

Full-Time

Sr. Director

International Marketing

Updated on 9/4/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Hardware
Biotechnology
Healthcare

Compensation Overview

$255k - $305kAnnually

+ Performance Bonus + Equity + Health Benefits

Senior, Expert

San Francisco, CA, USA

Category
General Marketing
Growth Marketing
Growth & Marketing
Required Skills
Market Research
Branding/Brand Strategy
Marketing
Requirements
  • 10+ years of commercial biotech or pharmaceutical experience, with at least six years in Marketing
  • Successful US & international launch experience in a competitive markets preferred
  • Demonstrated ability to develop actionable insights from complex clinical data and market research
  • Understanding of the drug development process, especially regarding opportunities for differentiation and value demonstration
  • Strong leadership skills and ability to influence functional stakeholders to set direction, align work efforts, and ensure outstanding execution
  • Excellent oral, written, and presentation skills
  • Ability to travel (~20%) is required
Responsibilities
  • Serve as the commercial representative on the International Expansion Team
  • Act as marketing lead for ROW territories
  • Ensure coordination and communication of global strategy and tactics
  • Support development of brand strategy, identifying opportunities and critical issues that can impact pipeline assets
  • Develop insights on the external environment, including competitive landscape, payer/reimbursement requirements, and unmet medical needs
  • Help identify and support the development of international key opinion leaders
  • Complete ROW market opportunity assessments and make recommendations on future expansion and asset indications/label expansions
  • Develop and track metrics to measure and ensure the success of marketing/promotional programs
  • Drive innovative approaches and address untapped opportunities
  • Partner with Medical Affairs on publication planning and medical education strategies
  • Partner with Value and Access to help develop the value proposition and access/ reimbursement strategies
  • Present business updates to Senior Team and partner with regional teams to ensure diverse commercial insights are brought into the planning process

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company operates using a decentralized subsidiary model, where each subsidiary concentrates on creating therapies for particular diseases while sharing central resources. This structure enhances efficiency and allows for the simultaneous advancement of multiple drug programs. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Unlike many competitors, BridgeBio emphasizes independent thinking and transparency, enabling rapid, data-driven decision-making. The company's goal is to create significant therapeutic advancements by targeting diseases at their genetic source, ultimately bringing effective treatments to market more quickly.

Company Stage

IPO

Total Funding

$6.8B

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

53%

2 year growth

56%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments, such as the $46.84 million from Norges Bank and $200 million for the oncology spinout, indicate strong financial backing and growth potential.
  • The launch of BridgeBio Oncology Therapeutics with $200 million in funding highlights the company's commitment to advancing cancer treatments, particularly KRAS inhibitors.
  • Equity grants to new employees under the Amended and Restated 2019 Inducement Equity Plan demonstrate BridgeBio's commitment to attracting and retaining top talent.

What critics are saying

  • The competitive landscape in genetic disease therapies and oncology is intense, with numerous companies vying for market share.
  • The decentralized subsidiary model, while efficient, may lead to challenges in maintaining cohesive strategic direction and operational alignment.

What makes BridgeBio unique

  • BridgeBio's decentralized subsidiary model allows for focused and efficient drug development across multiple genetic diseases simultaneously, unlike traditional centralized biopharma companies.
  • The company's emphasis on genetic diseases with well-understood causes enables targeted and potentially more effective therapies, setting it apart from competitors with broader, less focused pipelines.
  • BridgeBio's robust pipeline of over 15 drug programs targeting 20 different genetic diseases showcases its diversified approach, reducing the traditional biopharma process timeline.